who is developing retatrutide Demand for Unapproved Weight-Loss Drug Surges on Social Media Retatrutide—A Game Changer in Obesity

The CVOT results for the oral version of semaglutide (Rybelsus) are pending, with results expected soon

Underwriters are also getting better at detecting GLP-1 use through: Prescription databases Medical records requests Follow-up health questionnaires What This Means for Your Clients If currently on GLP-1 medications: Expect questions about medication use and duration Be prepared for potentially higher rates despite current health improvements Consider timing of application if they've been stable on medication for an extended period If recently stopped GLP-1 medications: Underwriters may view recent discontinuation as a risk factor Weight regain could further complicate the application process Medical follow-up showing sustained health improvements may help If planning to start GLP-1 medications: Understand that future applications may be affected by medication use Industry Trends to Watch Some forward-thinking insurance companies are exploring partnerships with GLP-1 providers to improve medication adherence

We are committed to navigating the complexities of "weight loss medication insurance" and prior authorizations so you can focus on reclaiming your health

Mild to moderate side effects are often observed in the early weeks (~first 6) of medication use and during dose escalation